Table 1.
Baseline characteristics at ICU admission.
| n (%) | |
|---|---|
| Age at time of HSCT, median (IQR) | 49 (35.0–57.0) |
| Male, N (%) | 114 (65.5) |
| Body mass index, median (IQR) | 22.7 (20.4–25.3) |
| Disease, N (%) | |
| AML | 66 (37.9) |
| MDS | 25 (14.4) |
| ALL | 30 (17.2) |
| MPN/CML | 28 (16.1) |
| Lymphoid diseases | 20 (11.5) |
| Multiple myeloma | 4 (2.3) |
| Aplastic anemia | 1 (0.6) |
| Donor, N (%)a | |
| Related | 61 (35.3) |
| Unrelated | 112 (64.7) |
| HLA constellation, N (%)a | |
| Matched | 145 (83.8) |
| Mismatched | 28 (16.2) |
| Graft source, N (%)a | |
| PBSC | 162 (93.6) |
| Bone marrow | 9 (5.2) |
| Cord blood | 2 (1.2) |
| Conditioning regime, N (%)a | |
| MAC | 107 (61.8) |
| RIC | 66 (38.2) |
| Global severity of cGvHD, N (%) | |
| Mild | 34 (19.5) |
| Moderate | 30 (17.2) |
| Severe | 110 (63.2) |
| cGvHD organ involvement, N (%) | |
| Skin | |
| - any score | 132 (76.7) |
| - score 2 | 47 (27.3) |
| - score 3 | 39 (22.7) |
| Lung | |
| - any score | 82 (47.1) |
| - score 2 | 15 (8.6) |
| - score 3 | 60 (34.5) |
| Liver | |
| - any score | 66 (38.2) |
| - score 2 | 15 (8.7) |
| - score 3 | 10 (5.8) |
| GI tract | |
| - any score | 41 (24.1) |
| - score 2 | 12 (7.1) |
| - score 3 | 12 (7.1) |
| Eyes | |
| - any score | 51 (29.3) |
| Mouth | |
| - any score | 46 (26.4) |
| Fascia | |
| - any score | 19 (10.9) |
| Serosa | |
| - any score | 4 (2.3) |
| Year of HSCT, median (IQR) | 2011 (2007–2015) |
| Year of ICU admission, median (IQR) | 2014 (2011–2017) |
| Time from HSCT to ICU admission, median days (IQR) | 550 (289–1149) |
| Time from cGvHD onset to ICU admission, median days (IQR)b | 357 (106–893) |
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, cGvHD chronic Graft-vs-Host disease, ICU intensive care unit, MAC myeloablative conditioning regimen, MDS myelodysplastic syndrome, MPN myeloproliferative syndrome, PBSC peripheral blood stem cells, RIC reduced-intensity conditioning regimen, HSCT allogeneic stem cell transplantation.
aNot applicable in n = 1.
bNot applicable in n = 12.